<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803647</url>
  </required_header>
  <id_info>
    <org_study_id>NSABP FC-6</org_study_id>
    <nct_id>NCT00803647</nct_id>
  </id_info>
  <brief_title>A Study With Neoadjuvant mFOLFOX7 Plus Cetuximab to Determine the Surgical Conversion Rate for Unresectable Colorectal Cancer With Metastases Confined to the Liver</brief_title>
  <official_title>A Phase II Study to Determine the Surgical Conversion Rate in Patients Receiving Neoadjuvant mFOLFOX7 + Cetuximab for Unresectable Wild-Type K-RAS Colorectal Cancer With Metastases Confined to the Liver</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NSABP Foundation Inc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NSABP Foundation Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      FC-6 is a Phase II, multi-center clinical trial for patients with unresectable, wild-type
      K-RAS, colorectal cancer with metastases confined to the liver. Liver metastases must be
      determined by FC-6 criteria to be unresectable, and the colorectal cancer (CRC) tumor
      (primary or metastatic) must be found to be wild-type K-RAS. Patients with mutant K-RAS
      tumors are ineligible. K-RAS testing can be done through the local hospital or a tumor sample
      can be submitted to the FC-6 central lab (Esoterix Clinical Trial Services).

      A primary aim of this study is to evaluate the surgical conversion rate using cytotoxic
      combination chemotherapy and biologic therapy with cetuximab, a monoclonal antibody targeted
      against the epidermal growth factor receptor. A second primary aim is to evaluate the safety
      and tolerability of a chemotherapy/targeted therapy regimen in this patient population.
      Secondary aims include determination of clinical response rate, recurrence-free survival for
      patients undergoing complete resection and/or ablation of liver metastases, and overall
      survival.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients will receive the FC-6 study treatment regimen every 2 weeks during each 8-week
      cycle for a total of 3 cycles.

      Baseline imaging of the chest, abdomen, and pelvis will be performed. CT scan or MRI of the
      abdomen will be performed after 1 cycle of neoadjuvant therapy to assess clinical response
      and resectability of liver metastases. If liver metastases are not deemed to be resectable at
      this assessment, but tumor assessment demonstrates stable disease or partial response,
      therapy will continue with re-assessment for clinical response and resectability after Cycle
      2 and, if necessary, after Cycle 3.

      After a minimum of 1 cycle of therapy, patients who meet the guidelines for resection of
      liver metastases will undergo liver metastasectomy (tumor resection and/or ablation) as soon
      as judged technically feasible by the hepatic surgeon in order to minimize chemotherapy
      damage to the liver and morbidity from surgery. At the investigator's discretion, the
      chemotherapy and cetuximab regimen may be continued for 1 additional treatment given at least
      2 weeks before the planned date of surgery. This additional treatment, if given, will not be
      considered to be part of the 3 study therapy cycles.

      The surgical goal is to perform a curative (R0) resection and/or ablation. If curative
      surgery was performed and if only 1 or 2 cycles of therapy were administered before surgery,
      postoperative therapy using the same regimen will resume 4-6 weeks following surgery to
      complete 3 cycles of study treatment. Following discontinuation of study therapy, all
      patients who undergo R0 resection (with or without ablation) will be followed every 3 months
      for the first 2 years on the study and then every 6 months for years 3 through 5.

      Further therapy for patients who do not undergo R0 resection/ablation will be at the
      investigator's discretion. These patients will only be followed for vital status every 12
      months for the remainder of the 5-year period following study entry.

      A total sample size of 60 patients will be enrolled in the FC-6 trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Reported Adverse Events.</measure>
    <time_frame>8 months</time_frame>
    <description>19 participants experienced at least one adverse event. There were a total of 95 adverse events reported. (Note: multiple occurrences of the same adverse event in one individual are counted only once.) Refer to the Adverse Events section for specifics. The Other Adverse Events section lists only those events occurring above 5% frequency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS). Time From Study Entry Until Death From Any Cause.</measure>
    <time_frame>18 months</time_frame>
    <description>The percentage of patients alive at 18 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.</measure>
    <time_frame>8 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET/CT, CT scan, MRI or spiral CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective clinical Response Rate (cRR) = CR + PR during the 3 preoperative cycles, among the treated patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab</intervention_name>
    <description>500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Erbitux</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>5-fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.</description>
    <arm_group_label>treatment</arm_group_label>
    <other_name>Eloxatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>leucovorin</intervention_name>
    <description>400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.</description>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Conditions for patient eligibility

          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0 or 1 and must be considered a potential candidate for a major hepatic surgical
             procedure.

          -  The patient must have histologic or cytologic confirmation of a diagnosis of
             colorectal adenocarcinoma.

          -  There must be documentation by PET/CT scan, CT scan, MRI, or intraoperative palpation
             (at the time of resection of the primary colorectal tumor, if applicable) that the
             patient has evidence of hepatic metastasis. (Histologic confirmation of hepatic
             metastasis is not required.)

          -  Patients are eligible with any of the following: primary tumor and regional nodes
             resected with clear surgical margins and no evidence of extrahepatic disease or;
             unresected primary tumor with plans to resect the primary tumor prior to study entry
             or; unresected primary tumor with plans to resect the primary tumor and the liver
             metastases in a single surgical procedure performed within 2-7 weeks after the last
             preoperative dose of chemotherapy/cetuximab or; unresected primary with plans to
             resect the primary tumor and the liver metastases in staged procedures performed
             within 2-7 weeks after the last preoperative dose of chemotherapy/cetuximab.

          -  The colorectal primary tumor or metastatic tumor must be determined to be wild-type
             K-RAS. The K-RAS test may have been performed through the local hospital, or a tumor
             sample may be submitted to the FC-6 central lab for K-RAS testing. If local K-RAS test
             results are reported as indeterminate, submission of a tumor sample for central
             testing is required. Note: Needle biopsy of liver metastasis is not recommended for
             the express purpose of obtaining tissue for K-RAS testing because of the risk of
             needle track dissemination of malignant cells.

          -  There must be documentation that the liver metastases must have been determined by a
             hepatic surgeon approved (by protocol defined criteria) to participate in FC-6 to be
             unresectable based on at least one of the following criteria: All of the liver
             metastases cannot be resected (and/or ablated) with negative margins, i.e., lesion(s)
             located in an area that would result in the resection of all of the hepatic veins or
             the main portal vein or the right and left hepatic arteries or the common bile duct;
             Complete resection and/or ablation would require greater than 60% of the liver
             parenchyma to be removed. Note: At the discretion of the hepatic surgeon, portal vein
             embolization (PVE) may be utilized preoperatively following neoadjuvant therapy to
             enhance the volume of the hepatic remnant. However, the determination of
             unresectability will be based on the estimate, at the time of study entry, of the
             percentage of liver parenchyma that would need to be removed. PVE may be employed
             preoperatively to enhance the overall safety, but not specifically the resectability
             of the liver metastasis(es).

          -  There must be documentation that: at least 3 of the 8 hepatic segments are free of
             metastases or; based on imaging studies, the patient is anticipated to have at least
             40% of the liver will remain intact after surgery.

          -  If an adjuvant therapy regimen of 5-FU given alone or in combination with leucovorin,
             irinotecan, capecitabine, oxaliplatin, cetuximab, or bevacizumab was administered, the
             adjuvant therapy must have been discontinued more than 6 months prior to study entry.

          -  The patient must have had the following tests and exams within 4 weeks prior to study
             entry: medical history and physical exam; consultation with a hepatic surgeon approved
             for FC-6; and PET/CT scan or both a PET scan and a CT scan of the chest, abdomen, and
             pelvis must be performed. (MRI scan can be substituted for the CT scan.)

          -  There must be evidence of adequate bone marrow function: absolute neutrophil count
             (ANC) greater than or equal to 1500/mm3; Hemoglobin greater than or equal to 10 g/dL;
             Platelets greater than or equal to 100,000/mm3

          -  There must be evidence of adequate hepatic function: Total bilirubin less than or
             equal to upper limit of normal (ULN) for the lab; aspartate aminotransferase (AST)
             less than or equal to 5.0 x ULN for the lab

          -  Serum creatinine must be less than or equal to 1.5 mg/dL.

        Conditions for patient ineligibility

          -  Diagnosis of anal or small bowel carcinoma.

          -  Colorectal cancers other than adenocarcinoma, e.g., sarcoma, lymphoma, carcinoid.

          -  Unresected primary tumor in the colon or rectum with significant symptoms related to
             obstruction or that will require radiation therapy.

          -  Evidence of extrahepatic metastases or non-contiguous extension of intrahepatic
             metastases to non-hepatic tissues.

          -  Radiographic evidence of metastases to portal lymph nodes (node greater than 1 cm in
             diameter) unless the node(s) are proven by biopsy to be negative.

          -  Previous hepatic resection and/or ablation, hepatic arterial infusion therapy, or any
             systemic therapy for metastatic disease. (Patients who have only had an excisional
             biopsy are eligible.)

          -  Radiation therapy to the liver.

          -  Pre-existing chronic hepatic disease (e.g., chronic active hepatitis, cirrhosis) that,
             in the opinion of the investigator and hepatic surgeon, would limit the patient's
             ability to undergo hepatic metastasectomy.

          -  Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 grade 3 or 4 anorexia or
             nausea related to metastatic disease.

          -  CTCAE v3.0 greater than or equal to grade 2 vomiting related to metastatic disease.

          -  CTCAE v3.0 greater than or equal to grade 2 sensory/motor neuropathy.

          -  Any of the following cardiac conditions: Documented congestive heart failure;
             Myocardial infarction within 6 months prior to study entry; Unstable angina within 6
             months prior to study entry; Symptomatic arrhythmia.

          -  Serious or non-healing wound, skin ulcers, or bone fracture.

          -  History of bleeding diathesis or coagulopathy. (Patients on stable anticoagulant
             therapy are eligible.)

          -  Symptomatic interstitial lung disease or definitive evidence of interstitial lung
             disease described on CT scan, MRI, or chest x-ray in asymptomatic patients.

          -  Any evidence of active infection.

          -  Active inflammatory bowel disease.

          -  Other malignancies unless the patient is considered to be disease-free and has
             completed therapy for the malignancy greater than or equal to 12 months prior to study
             entry. Patients with the following cancers are eligible if diagnosed and treated
             within the past 12 months: carcinoma in situ of the cervix, colorectal carcinoma in
             situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.

          -  Previous serious hypersensitivity reaction to monoclonal antibodies.

          -  Psychiatric or addictive disorders or other conditions that, in the opinion of the
             investigator, would preclude the patient from meeting the study requirements.

          -  Pregnancy or lactation at the time of study entry. (WOCBP must have a negative
             pregnancy test within 2 weeks prior to study entry. Male and female patients of
             reproductive potential must agree to use adequate contraceptive methods during and for
             2 months after study therapy. )

          -  Any other serious concomitant medical condition that, in the opinion of the
             investigator, would compromise the safety of the patient or compromise the patient's
             ability to participate in the study.

          -  Use of any investigational product within 30 days prior to study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Norman Wolmark, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NSABP Foundation Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center - Vallejo</name>
      <address>
        <city>Vallejo</city>
        <state>California</state>
        <zip>94589</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M.D. Anderson Cancer Center - Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hospital</name>
      <address>
        <city>Naperville</city>
        <state>Illinois</state>
        <zip>60566</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NortonHealthcare, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202-5070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franklin Square Hospital Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Grand Rapids Clinical Oncology Program</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP, William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Metro-Minnesota</name>
      <address>
        <city>Saint Louis Park</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP, Dayton, OH</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Cancer Center at Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NSABP Foundation, Inc.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Upstate Carolina</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vermont Cancer Center at University of Vermont</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05405-0075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <results_first_submitted>October 19, 2015</results_first_submitted>
  <results_first_submitted_qc>July 26, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 14, 2016</results_first_posted>
  <last_update_submitted>April 6, 2018</last_update_submitted>
  <last_update_submitted_qc>April 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSABP</keyword>
  <keyword>Cetuximab</keyword>
  <keyword>FOLFOX7</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>5-FU</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>KRAS wild type</keyword>
  <keyword>metastatic colorectal cancer</keyword>
  <keyword>Erbitux</keyword>
  <keyword>Eloxatin</keyword>
  <keyword>Liver resection</keyword>
  <keyword>Liver ablation</keyword>
  <keyword>Metastasectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment</title>
          <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Gender data were not collected.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).</title>
        <time_frame>8 months</time_frame>
        <population>All 20 patients were included in this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or Ablated With no Postoperative Evidence of Residual Malignant Disease (R0 Resection).</title>
          <population>All 20 patients were included in this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="50.9" upper_limit="91.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reported Adverse Events.</title>
        <description>19 participants experienced at least one adverse event. There were a total of 95 adverse events reported. (Note: multiple occurrences of the same adverse event in one individual are counted only once.) Refer to the Adverse Events section for specifics. The Other Adverse Events section lists only those events occurring above 5% frequency.</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Adverse Events.</title>
          <description>19 participants experienced at least one adverse event. There were a total of 95 adverse events reported. (Note: multiple occurrences of the same adverse event in one individual are counted only once.) Refer to the Adverse Events section for specifics. The Other Adverse Events section lists only those events occurring above 5% frequency.</description>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS). Time From Study Entry Until Death From Any Cause.</title>
        <description>The percentage of patients alive at 18 months.</description>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS). Time From Study Entry Until Death From Any Cause.</title>
          <description>The percentage of patients alive at 18 months.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.8" lower_limit="57.7" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET/CT, CT scan, MRI or spiral CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective clinical Response Rate (cRR) = CR + PR during the 3 preoperative cycles, among the treated patients.</description>
        <time_frame>8 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Clinical Response Rate (cRR). Measureable Lesions That Can be Accurately Measured in at Least One Dimension With Conventional Radiologic Techniques or Spiral CT.</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by PET/CT, CT scan, MRI or spiral CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Objective clinical Response Rate (cRR) = CR + PR during the 3 preoperative cycles, among the treated patients.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85" lower_limit="62.1" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.</title>
        <time_frame>2 years</time_frame>
        <population>Patients with R0 resection</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrence-free Survival (RFS). Time From Study Entry Until First Recurrence.</title>
          <population>Patients with R0 resection</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" lower_limit="5.5" upper_limit="23.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>mFOLFOX7 (5-FU, leucovorin, oxaliplatin) + cetuximab</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>arhythmia supraventricular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>thrombosis in device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>septic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Cavernous sinus thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>vascular access complication</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>platelet count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>deep vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>venous thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>anaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>lymphopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetitie</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hyperglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>hypoalbuminaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>exfoliative rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>dermatitis acneiform</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Diana Gosik, Director Department of Site and Study Management</name_or_title>
      <organization>NSABP Foundation</organization>
      <phone>412-339-5333</phone>
      <email>diana.gosik@nsabp.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

